{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T05:13:49.496945+00:00","company":{"ticker":"HALO","cik":1159036,"company_name":"HALOZYME THERAPEUTICS, INC."},"pagination":{"limit":100,"returned":39,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"lender":[{"display_name":"The Bank of New York Mellon Trust Company, N.A.","detail":"convertible_notes","count":2,"first_seen":"2025-11-12T23:59:59+00:00","last_seen":"2025-11-12T23:59:59+00:00","evidence_fact_ids":[38268,38269]}]},"facts":[{"fact_type":"earnings_release","fact_key":"ec0345d857143f2f9d9fb3f665371e404b9ef319","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2026-05-11T20:06:06+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter ended March 31, 2026","report_date":"2026-05-11","result_type":"reported_results","revenue_text":null},"claim":"HALOZYME THERAPEUTICS, INC. updated its first quarter ended March 31, 2026 guidance (reaffirmed).","evidence_excerpt":"On May 11, 2026, Halozyme Therapeutics, Inc. issued a press release to report its financial results for the first quarter ended March 31, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001159036-26-000067","anchor_url":"https://secwatch.observer/filing/0001159036-26-000067#claim-ec0345d857143f2f9d9fb3f665371e404b9ef319","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000067/0001159036-26-000067-index.htm"},{"fact_type":"shareholder_vote","fact_key":"3e55e38ec321cc4d7b0e3b3eeb4cde3aae13cc8e","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2026-05-07T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-05","outcome":"passed","proposal_text":"Ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"91,232","votes_against":"849,433","votes_for":"103,197,579","votes_withheld":null}]},"claim":"HALOZYME THERAPEUTICS, INC. shareholders approved Ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-05 meeting.","evidence_excerpt":"Proposal 3: The vote on a proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was as follows: Votes For Votes Against Abstain Broker Non-Votes 103,197,579 849,433 91,232 --- The foregoing proposal was approved.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001159036-26-000057","anchor_url":"https://secwatch.observer/filing/0001159036-26-000057#claim-3e55e38ec321cc4d7b0e3b3eeb4cde3aae13cc8e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000057/0001159036-26-000057-index.htm"},{"fact_type":"shareholder_vote","fact_key":"81ee7d127e730c5f33c8b2f096b86dad889081b5","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2026-05-07T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-05","outcome":"passed","proposal_text":"Advisory vote on the compensation of the Company's named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"9,889,219","subject":null,"votes_abstain":"255,081","votes_against":"9,311,426","votes_for":"84,682,518","votes_withheld":null}]},"claim":"HALOZYME THERAPEUTICS, INC. shareholders approved Advisory vote on the compensation of the Company's named executive officers at the 2026-05-05 meeting.","evidence_excerpt":"Proposal 2: The advisory vote on the compensation of the Company's named executive officers was as follows: Votes For Votes Against Abstain Broker Non-Votes 84,682,518 9,311,426 255,081 9,889,219 The foregoing proposal was approved.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001159036-26-000057","anchor_url":"https://secwatch.observer/filing/0001159036-26-000057#claim-81ee7d127e730c5f33c8b2f096b86dad889081b5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000057/0001159036-26-000057-index.htm"},{"fact_type":"shareholder_vote","fact_key":"ce6546d9cc0d6d77e7d66bc062620b60a66938bc","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2026-05-07T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-05","outcome":"passed","proposal_text":"Election of two Class I directors to hold office for a three-year term expiring at the 2029 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified","proposal_type":"director_election","results":[{"broker_non_votes":"9,889,219","subject":"Bernadette Connaughton","votes_abstain":"127,131","votes_against":"5,068,160","votes_for":"89,053,734","votes_withheld":null},{"broker_non_votes":"9,889,219","subject":"Matthew L. Posard","votes_abstain":"1,272,714","votes_against":"10,236,878","votes_for":"82,739,433","votes_withheld":null}]},"claim":"HALOZYME THERAPEUTICS, INC. shareholders approved Election of two Class I directors to hold office for a three-year term expiring at the 2029 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified at the 2026-05-05 meeting.","evidence_excerpt":"Proposal 1 : Election of two Class I directors to hold office for a three-year term expiring at the 2029 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified: Names Votes For Votes Against Abstain Broker Non-Votes Bernadette Connaughton 89,053,734 5,068,160 127,131 9,889,219 Matthew L. Posard 82,739,433 10,236,878 1,272,714 9,889,219 Each of the foregoing candidates was elected and each received affirmative votes from more than a majority of the outstanding shares.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001159036-26-000057","anchor_url":"https://secwatch.observer/filing/0001159036-26-000057#claim-ce6546d9cc0d6d77e7d66bc062620b60a66938bc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000057/0001159036-26-000057-index.htm"},{"fact_type":"executive_change","fact_key":"4d5a33948e","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2026-04-30T23:59:59+00:00","payload":{"action":"will assume an advisory role","action_category":"role_change","departure_tone":"routine","effective_date":"2026-06-08","interim":false,"role":"Interim CFO","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"David Ramsay changed role as Interim CFO at HALOZYME THERAPEUTICS, INC..","evidence_excerpt":"Effective as of June 8, 2026, David Ramsay, the Company’s current Interim CFO, will assume an advisory role with the Company to assist during a brief transition period.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001159036-26-000053","anchor_url":"https://secwatch.observer/filing/0001159036-26-000053#claim-4d5a33948e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000053/0001159036-26-000053-index.htm"},{"fact_type":"executive_change","fact_key":"8b0dab755f","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2026-04-30T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2026-06-08","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Darren Snellgrove was appointed as Chief Financial Officer at HALOZYME THERAPEUTICS, INC..","evidence_excerpt":"On April 30, 2026, Halozyme Therapeutics, Inc. (the “Company”) announced that Darren Snellgrove has been appointed to serve as the Company’s Chief Financial Officer (“CFO”), effective June 8, 2026.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001159036-26-000053","anchor_url":"https://secwatch.observer/filing/0001159036-26-000053#claim-8b0dab755f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000053/0001159036-26-000053-index.htm"},{"fact_type":"governance_change","fact_key":"02bf475624c5b9ce604577f21b73ef671d4f71f2","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2026-04-24T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2026-04-22","item_codes_triggered":["5.03"],"summary_text":"Amended Bylaws to revise director removal standard and restrict stockholder action by written consent"},"claim":"HALOZYME THERAPEUTICS, INC.: Amended Bylaws to revise director removal standard and restrict stockholder action by written consent (effective 2026-04-22).","evidence_excerpt":"On April 22, 2026, the Board of Directors (the “Board”) of Halozyme Therapeutics, Inc. (the “Company”) amended the Company’s Bylaws to revise (i) Section 2.5 to provide that directors may be removed from office at any time, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of the directors and (ii) Section 1.12 to clarify that any action required to be taken at any annual or special meeting of stockholders of the corporation, or any action which may be taken at any annual or special meeting of such stockholders, may not be taken without a meeting, consistent with Article FIFTH of the Certificate of Incorporation.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001159036-26-000051","anchor_url":"https://secwatch.observer/filing/0001159036-26-000051#claim-02bf475624c5b9ce604577f21b73ef671d4f71f2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000051/0001159036-26-000051-index.htm"},{"fact_type":"equity_issuance","fact_key":"5be8301be1f9756ebbeafd01abbda98bd3691dea","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2025-11-12T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"net proceeds of approximately $1.47 billion after deducting discounts, commissions, and offering expenses","effective_date":"2025-11-12","item_codes_triggered":["3.02"],"purchaser":"initial purchasers (subsequently resold to qualified institutional buyers)","security_type":"convertible_note","shares_text":"$1,500.0 million aggregate principal amount of convertible senior notes, consisting of $750.0 million of 0% Convertible Senior Notes due 2031 and $750.0 million"},"claim":"HALOZYME THERAPEUTICS, INC. issued $1,500.0 million aggregate principal amount of convertible senior notes, consisting of $750.0 million of 0% Convertible Senior Notes due 2031 and $750.0 million of convertible note to initial purchasers (subsequently resold to qualified institutional buyers) for net proceeds of approximately $1.47 billion after deducting discounts, commissions, and offering expenses.","evidence_excerpt":"from registration requirements, or in a transaction not subject to, such registration requirements. The Company received net proceeds from the offering of approximately $1.47 billion after deducting the Initial Purchasers’ discounts and commissions and the Company’s estimated offering expenses. The Company used approximately $182.7 million of the net proceeds","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-277988","anchor_url":"https://secwatch.observer/filing/0001193125-25-277988#claim-5be8301be1f9756ebbeafd01abbda98bd3691dea","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/0001193125-25-277988-index.htm"},{"fact_type":"debt_financing","fact_key":"4023164b88656f389fbe724296629805c43ea1f8","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2025-11-12T23:59:59+00:00","payload":{"counterparty":"The Bank of New York Mellon Trust Company, N.A.","effective_date":"2025-11-12","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"0.875%","item_codes_triggered":["2.03"],"maturity_text":"due 2032","principal_text":"$750.0 million in aggregate principal amount"},"claim":"HALOZYME THERAPEUTICS, INC. incurred convertible notes of $750.0 million in aggregate principal amount with The Bank of New York Mellon Trust Company, N.A. at 0.875% maturing due 2032.","evidence_excerpt":"(ii) $750.0 million in aggregate principal amount of 0.875% Convertible Senior Notes due 2032","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-25-277988","anchor_url":"https://secwatch.observer/filing/0001193125-25-277988#claim-4023164b88656f389fbe724296629805c43ea1f8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/0001193125-25-277988-index.htm"},{"fact_type":"debt_financing","fact_key":"39299b5f85f3387bb8b6a71138eebe8f85593e3b","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2025-11-12T23:59:59+00:00","payload":{"counterparty":"The Bank of New York Mellon Trust Company, N.A.","effective_date":"2025-11-12","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"0%","item_codes_triggered":["2.03"],"maturity_text":"due 2031","principal_text":"$1,500.0 million aggregate principal amount"},"claim":"HALOZYME THERAPEUTICS, INC. incurred convertible notes of $1,500.0 million aggregate principal amount with The Bank of New York Mellon Trust Company, N.A. at 0% maturing due 2031.","evidence_excerpt":"completed its previously announced sale of $1,500.0 million aggregate principal amount convertible senior notes, consisting of (i) $750.0 million of 0% Convertible Senior Notes due 2031","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-25-277988","anchor_url":"https://secwatch.observer/filing/0001193125-25-277988#claim-39299b5f85f3387bb8b6a71138eebe8f85593e3b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000119312525277988/0001193125-25-277988-index.htm"},{"fact_type":"executive_change","fact_key":"ed26e620fa","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2025-03-21T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"retirement","effective_date":"2025-03-17","interim":false,"role":"Senior Vice President, Chief Technical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Michael J. LaBarre retired as Senior Vice President, Chief Technical Officer at HALOZYME THERAPEUTICS, INC..","evidence_excerpt":"On March 17, 2025, Michael J. LaBarre, Senior Vice President, Chief Technical Officer of Halozyme Therapeutics, Inc. (the “Company”) notified the Company of his decision to retire from the Company, effective March 17, 2025.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001159036-25-000020","anchor_url":"https://secwatch.observer/filing/0001159036-25-000020#claim-ed26e620fa","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903625000020/0001159036-25-000020-index.htm"},{"fact_type":"executive_change","fact_key":"145b65537e","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2025-02-13T23:59:59+00:00","payload":{"action":"notified intention not to stand for reelection","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Connie L. Matsui departed as Director at HALOZYME THERAPEUTICS, INC..","evidence_excerpt":"On February 11, 2025, Connie L. Matsui, a member of the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”), notified the Company of her intention not to stand for reelection at the Company’s 2025 annual meeting of stockholders.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001159036-25-000005","anchor_url":"https://secwatch.observer/filing/0001159036-25-000005#claim-145b65537e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903625000005/0001159036-25-000005-index.htm"},{"fact_type":"earnings_release","fact_key":"303f2d0710754b66904b6138dfe4fcec03e9bef6","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2024-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$76.8 million","period_text":"the first quarter ended March 31, 2024","report_date":"2024-05-07","result_type":"reported_results","revenue_text":"$195.9 million"},"claim":"HALOZYME THERAPEUTICS, INC. reported the first quarter ended March 31, 2024 results: revenue $195.9 million, net income $76.8 million. Guidance reaffirmed.","evidence_excerpt":"any general incorporation language in such filing. \n\n--- EX-99.1 (EX-99.1) ---\n\nHALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS Revenue Increased 21% YOY to $196 million; Net Income of $77 million; Adjusted EBITDA of $116 million; GAAP Diluted EPS of $0.60 and Non-GAAP Diluted EPS of $0.79 1 Royalty Revenue Increased 21% YOY to $121 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001159036-24-000036","anchor_url":"https://secwatch.observer/filing/0001159036-24-000036#claim-303f2d0710754b66904b6138dfe4fcec03e9bef6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000036/0001159036-24-000036-index.htm"},{"fact_type":"shareholder_vote","fact_key":"f1d205e32510eb87d7e5d9d20f446816b429e734","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2024-04-26T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-04-25","outcome":"passed","proposal_text":"Ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"—","subject":null,"votes_abstain":"121,443","votes_against":"647,868","votes_for":"114,912,469","votes_withheld":null}]},"claim":"HALOZYME THERAPEUTICS, INC. shareholders approved Ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 at the 2024-04-25 meeting.","evidence_excerpt":"Proposal 4 : The vote on a proposal to ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 was as follows: Votes For Votes Against Abstain Broker Non-Votes 114,912,469 647,868 121,443 — The foregoing proposal was approved.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001159036-24-000031","anchor_url":"https://secwatch.observer/filing/0001159036-24-000031#claim-f1d205e32510eb87d7e5d9d20f446816b429e734","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000031/0001159036-24-000031-index.htm"},{"fact_type":"shareholder_vote","fact_key":"bdeb9179ff0be060d7310c435dbdd87c80c78ce6","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2024-04-26T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-04-25","outcome":"passed","proposal_text":"Approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding exculpation of officers","proposal_type":"charter_amendment","results":[{"broker_non_votes":"10,383,116","subject":null,"votes_abstain":"173,796","votes_against":"13,612,616","votes_for":"91,512,252","votes_withheld":null}]},"claim":"HALOZYME THERAPEUTICS, INC. shareholders approved Approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding exculpation of officers at the 2024-04-25 meeting.","evidence_excerpt":"Proposal 3: The vote on a proposal to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding exculpation of officers was as follows: Votes For Votes Against Abstain Broker Non-Votes 91,512,252 13,612,616 173,796 10,383,116 The foregoing proposal was approved.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001159036-24-000031","anchor_url":"https://secwatch.observer/filing/0001159036-24-000031#claim-bdeb9179ff0be060d7310c435dbdd87c80c78ce6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000031/0001159036-24-000031-index.htm"},{"fact_type":"shareholder_vote","fact_key":"b32b7570c1ee55f7316203f5c8262038b56f66e9","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2024-04-26T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-04-25","outcome":"passed","proposal_text":"The advisory vote on the compensation of the Company’s named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"10,383,116","subject":null,"votes_abstain":"247,626","votes_against":"2,190,603","votes_for":"102,860,435","votes_withheld":null}]},"claim":"HALOZYME THERAPEUTICS, INC. shareholders approved The advisory vote on the compensation of the Company’s named executive officers at the 2024-04-25 meeting.","evidence_excerpt":"Proposal 2 : The advisory vote on the compensation of the Company’s named executive officers was as follows: Votes For Votes Against Abstain Broker Non-Votes 102,860,435 2,190,603 247,626 10,383,116 The foregoing proposal was approved.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001159036-24-000031","anchor_url":"https://secwatch.observer/filing/0001159036-24-000031#claim-b32b7570c1ee55f7316203f5c8262038b56f66e9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000031/0001159036-24-000031-index.htm"},{"fact_type":"shareholder_vote","fact_key":"87f33d4cfbc5175dfe842a6c208da2b76e9e6e18","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2024-04-26T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-04-25","outcome":"passed","proposal_text":"Election of two Class II directors to hold office for a three-year term expiring at the 2027 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified","proposal_type":"director_election","results":[{"broker_non_votes":"10,383,116","subject":"Barbara Duncan","votes_abstain":"161,704","votes_against":"15,016,536","votes_for":"90,120,424","votes_withheld":null},{"broker_non_votes":"10,383,116","subject":"Mahesh Krishnan, M.D.","votes_abstain":"165,984","votes_against":"1,164,017","votes_for":"103,968,663","votes_withheld":null}]},"claim":"HALOZYME THERAPEUTICS, INC. shareholders approved Election of two Class II directors to hold office for a three-year term expiring at the 2027 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified at the 2024-04-25 meeting.","evidence_excerpt":"Proposal 1 : Election of two Class II directors to hold office for a three-year term expiring at the 2027 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified: Names Votes For Votes Against Abstain Broker Non-Votes Barbara Duncan 90,120,424 15,016,536 161,704 10,383,116 Mahesh Krishnan, M.D. 103,968,663 1,164,017 165,984 10,383,116 Each of the foregoing candidates was elected and each received affirmative votes from more than a majority of the outstanding shares.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001159036-24-000031","anchor_url":"https://secwatch.observer/filing/0001159036-24-000031#claim-87f33d4cfbc5175dfe842a6c208da2b76e9e6e18","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000031/0001159036-24-000031-index.htm"},{"fact_type":"earnings_release","fact_key":"155dd68cb014794ec12526880443f74f66262fa1","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2024-02-20T23:59:59+00:00","payload":{"eps_text":"$3.55-3.90","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"2024","report_date":"2024-02-20","result_type":"guidance_update","revenue_text":"$915-985 Million"},"claim":"HALOZYME THERAPEUTICS, INC. reported 2024 results: revenue $915-985 Million, EPS $3.55-3.90. Guidance reaffirmed.","evidence_excerpt":"Reiterating 2024 Financial Guidance: Total Revenue of $915-985 Million, Representing YOY Growth of 10-19%, Adjusted EBITDA of $535-585 Million, Representing YOY Growth of 26- 37% and Non-GAAP Diluted EPS of $3.55-3.90, Representing YOY Growth of 28-41%","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001159036-24-000007","anchor_url":"https://secwatch.observer/filing/0001159036-24-000007#claim-155dd68cb014794ec12526880443f74f66262fa1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000007/0001159036-24-000007-index.htm"},{"fact_type":"earnings_release","fact_key":"6f9e3e1a3e01f108ce6554d64e6c1c4f0e889dad","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2024-02-20T23:59:59+00:00","payload":{"eps_text":"$2.10","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"Full Year 2023","report_date":"2024-02-20","result_type":"reported_results","revenue_text":"$829.3 million"},"claim":"HALOZYME THERAPEUTICS, INC. reported Full Year 2023 results: revenue $829.3 million, EPS $2.10.","evidence_excerpt":"Full Year 2023 Revenue Increased 26% YOY to $829 million; GAAP Diluted EPS of $2.10 and Non-GAAP Diluted EPS of $2.77","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001159036-24-000007","anchor_url":"https://secwatch.observer/filing/0001159036-24-000007#claim-6f9e3e1a3e01f108ce6554d64e6c1c4f0e889dad","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000007/0001159036-24-000007-index.htm"},{"fact_type":"earnings_release","fact_key":"b99af6b0cdfc4bdba6bfa680b4aa45bb75e5e1de","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2024-02-20T23:59:59+00:00","payload":{"eps_text":"$0.65","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"Fourth Quarter 2023","report_date":"2024-02-20","result_type":"reported_results","revenue_text":"$230.0 million"},"claim":"HALOZYME THERAPEUTICS, INC. reported Fourth Quarter 2023 results: revenue $230.0 million, EPS $0.65.","evidence_excerpt":"Fourth Quarter Revenue Increased 27% YOY to $230 million; GAAP Diluted EPS of $0.65 and Non-GAAP Diluted EPS of $0.82","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001159036-24-000007","anchor_url":"https://secwatch.observer/filing/0001159036-24-000007#claim-b99af6b0cdfc4bdba6bfa680b4aa45bb75e5e1de","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000007/0001159036-24-000007-index.htm"},{"fact_type":"earnings_release","fact_key":"36230b0984b9aa7e75907b0ac1a1f9afc64f5c30","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2024-01-17T23:59:59+00:00","payload":{"eps_text":"GAAP Diluted EPS $2.18 to $2.21 ; Non-GAAP Diluted EPS $2.77 to $2.80","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$292 million to $297 million","period_text":"Twelve Months Ended December 31, 2023","report_date":"2024-01-17","result_type":"preliminary_results","revenue_text":"$827 million to $832 million"},"claim":"HALOZYME THERAPEUTICS, INC. reported Twelve Months Ended December 31, 2023 results: revenue $827 million to $832 million, net income $292 million to $297 million, EPS GAAP Diluted EPS $2.18 to $2.21 ; Non-GAAP Diluted EPS $2.77 to $2.80.","evidence_excerpt":"this preliminary information. Unaudited Preliminary Estimates of Results for the Twelve Months Ended December 31, 2023 The Company estimates 2023 Revenue will be in the range of $827 million to $832 million. The Company estimates 2023 royalties will be in the range of $445 million to $450 million. The Company estimates 2023 Net Income will be in the range of $292","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001159036-24-000003","anchor_url":"https://secwatch.observer/filing/0001159036-24-000003#claim-36230b0984b9aa7e75907b0ac1a1f9afc64f5c30","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000003/0001159036-24-000003-index.htm"},{"fact_type":"earnings_release","fact_key":"4e12191c9fc154ce7850611e1a8b9eaadd2667b2","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2023-11-06T23:59:59+00:00","payload":{"eps_text":"$0.61","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"third quarter ended September 30, 2023","report_date":"2023-11-06","result_type":"reported_results","revenue_text":"$216.0 million"},"claim":"HALOZYME THERAPEUTICS, INC. reported third quarter ended September 30, 2023 results: revenue $216.0 million, EPS $0.61. Guidance raised.","evidence_excerpt":"endpoints in patients with relapsing forms of multiple sclerosis (“MS”) or primary progressive MS (“RMS” or “PPMS”). Third Quarter 2023 Financial Highlights: • Revenue was $216.0 million compared to $209.0 million in the third quarter of 2022. The 3% year-over-year increase was driven by growth in ENHANZE ® revenue streams with an increase in royalty revenue and","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001159036-23-000056","anchor_url":"https://secwatch.observer/filing/0001159036-23-000056#claim-4e12191c9fc154ce7850611e1a8b9eaadd2667b2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000056/0001159036-23-000056-index.htm"},{"fact_type":"earnings_release","fact_key":"e226ad080642e90bbfc6708b2beef3a37d18b292","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2023-05-09T23:59:59+00:00","payload":{"eps_text":"$0.29","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$39.6 million","period_text":"the first quarter ended March 31, 2023","report_date":"2023-05-09","result_type":"reported_results","revenue_text":"$162.1 million"},"claim":"HALOZYME THERAPEUTICS, INC. reported the first quarter ended March 31, 2023 results: revenue $162.1 million, net income $39.6 million, EPS $0.29. Guidance reaffirmed.","evidence_excerpt":"any general incorporation language in such filing. \n\n--- EX-99.1 (EX-99.1) ---\n\nHALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS Revenue Increased 38% YOY to $162.1 million; GAAP Diluted Earnings per Share of $0.29 and Non-GAAP Diluted Earnings per Share of $0.47 1 Royalty Revenue Increased 43% YOY to $99.6 million Reiterating 2023 Revenue Guidance","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001159036-23-000037","anchor_url":"https://secwatch.observer/filing/0001159036-23-000037#claim-e226ad080642e90bbfc6708b2beef3a37d18b292","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000037/0001159036-23-000037-index.htm"},{"fact_type":"shareholder_vote","fact_key":"2cff2da9b06e37dda51030b9cb70661968e50213","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2023-05-08T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-05","outcome":"passed","proposal_text":"A proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"—","subject":null,"votes_abstain":"103,055","votes_against":"1,153,279","votes_for":"123,271,829","votes_withheld":null}]},"claim":"HALOZYME THERAPEUTICS, INC. shareholders approved A proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-05 meeting.","evidence_excerpt":"Proposal 4 : The vote on a proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 was as follows: Votes For Votes Against Abstain Broker Non-Votes 123,271,829 1,153,279 103,055 — The foregoing proposal was approved.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001159036-23-000033","anchor_url":"https://secwatch.observer/filing/0001159036-23-000033#claim-2cff2da9b06e37dda51030b9cb70661968e50213","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000033/0001159036-23-000033-index.htm"},{"fact_type":"shareholder_vote","fact_key":"17e8cd4726837ceee787679679b324f41f9d5dbb","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2023-05-08T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-05","outcome":"passed","proposal_text":"The advisory vote on the frequency of holding future advisory votes on the compensation of the Company’s named executive officers","proposal_type":"say_on_pay_frequency","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"1,760,124","votes_against":"145,264","votes_for":"110,411,006","votes_withheld":null}]},"claim":"HALOZYME THERAPEUTICS, INC. shareholders approved The advisory vote on the frequency of holding future advisory votes on the compensation of the Company’s named executive officers at the 2023-05-05 meeting.","evidence_excerpt":"Proposal 3 : The advisory vote on the frequency of holding future advisory votes on the compensation of the Company’s named executive officers was as follows: One Year Two Years Three Years Abstain 110,411,006 145,264 1,760,124 83,512","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001159036-23-000033","anchor_url":"https://secwatch.observer/filing/0001159036-23-000033#claim-17e8cd4726837ceee787679679b324f41f9d5dbb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000033/0001159036-23-000033-index.htm"},{"fact_type":"shareholder_vote","fact_key":"2f52e7805e1023b32abd442933ce160fbc720c63","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2023-05-08T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-05","outcome":"passed","proposal_text":"The advisory vote on the compensation of the Company's named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"12,128,257","subject":null,"votes_abstain":"114,096","votes_against":"4,657,698","votes_for":"107,628,112","votes_withheld":null}]},"claim":"HALOZYME THERAPEUTICS, INC. shareholders approved The advisory vote on the compensation of the Company's named executive officers at the 2023-05-05 meeting.","evidence_excerpt":"Proposal 2 : The advisory vote on the compensation of the Company's named executive officers was as follows: Votes For Votes Against Abstain Broker Non-Votes 107,628,112 4,657,698 114,096 12,128,257 The foregoing proposal was approved.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001159036-23-000033","anchor_url":"https://secwatch.observer/filing/0001159036-23-000033#claim-2f52e7805e1023b32abd442933ce160fbc720c63","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000033/0001159036-23-000033-index.htm"},{"fact_type":"shareholder_vote","fact_key":"61699236eb404f7f27c7d3c03a841e1c5d4a3a2c","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2023-05-08T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-05","outcome":"passed","proposal_text":"Election of three Class I directors to hold office for a three-year term expiring at the 2026 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified","proposal_type":"director_election","results":[{"broker_non_votes":"12,128,257","subject":"Bernadette Connaughton","votes_abstain":"121,451","votes_against":"2,629,860","votes_for":"109,648,595","votes_withheld":null},{"broker_non_votes":"12,128,257","subject":"Moni Miyashita","votes_abstain":"122,513","votes_against":"2,329,204","votes_for":"109,948,189","votes_withheld":null},{"broker_non_votes":"12,128,257","subject":"Matthew L. Posard","votes_abstain":"123,130","votes_against":"16,598,543","votes_for":"95,678,233","votes_withheld":null}]},"claim":"HALOZYME THERAPEUTICS, INC. shareholders approved Election of three Class I directors to hold office for a three-year term expiring at the 2026 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified at the 2023-05-05 meeting.","evidence_excerpt":"On May 5, 2023, Halozyme Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001159036-23-000033","anchor_url":"https://secwatch.observer/filing/0001159036-23-000033#claim-61699236eb404f7f27c7d3c03a841e1c5d4a3a2c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000033/0001159036-23-000033-index.htm"},{"fact_type":"executive_change","fact_key":"de6110e3a4","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2023-02-23T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-12-31","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"James M. Daly resigned as Director at HALOZYME THERAPEUTICS, INC..","evidence_excerpt":"On February 22, 2023, James M. Daly, a member of the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”), notified the Company of his intention to resign from the Company’s Board of Directors effective at the end of the 2023 calendar year.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001159036-23-000014","anchor_url":"https://secwatch.observer/filing/0001159036-23-000014#claim-de6110e3a4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000014/0001159036-23-000014-index.htm"},{"fact_type":"earnings_release","fact_key":"62251297e1265d590af011ad8f0b8370cfc74b4c","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2023-02-21T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"initiated","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"2023","report_date":"2023-02-21","result_type":"guidance_update","revenue_text":"$815 million to $845 million"},"claim":"HALOZYME THERAPEUTICS, INC. reported 2023 results: revenue $815 million to $845 million. Guidance initiated.","evidence_excerpt":"2023 Revenue Guidance of $815 million to $845 million, Representing 23%-28% YOY Growth; EBITDA of $415 million to $440 million, Representing >30% YOY Growth","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001159036-23-000011","anchor_url":"https://secwatch.observer/filing/0001159036-23-000011#claim-62251297e1265d590af011ad8f0b8370cfc74b4c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000011/0001159036-23-000011-index.htm"},{"fact_type":"earnings_release","fact_key":"278df542fa5c8a7befe54137e71caf5e18b7b476","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2023-02-21T23:59:59+00:00","payload":{"eps_text":"$1.44 per diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the full year ended December 31, 2022","report_date":"2023-02-21","result_type":"reported_results","revenue_text":"$660.1 million"},"claim":"HALOZYME THERAPEUTICS, INC. reported the full year ended December 31, 2022 results: revenue $660.1 million, EPS $1.44 per diluted share.","evidence_excerpt":"Full Year 2022 Revenue Increased 49% YOY to $660.1 million; GAAP Diluted Earnings per Share of $1.44 and Non-GAAP Diluted Earnings per Share of $2.21","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001159036-23-000011","anchor_url":"https://secwatch.observer/filing/0001159036-23-000011#claim-278df542fa5c8a7befe54137e71caf5e18b7b476","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000011/0001159036-23-000011-index.htm"},{"fact_type":"earnings_release","fact_key":"e10f0527f9e778fe3c9ce8837b5f55b6f055aabf","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2023-02-21T23:59:59+00:00","payload":{"eps_text":"$0.42 per diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter ended December 31, 2022","report_date":"2023-02-21","result_type":"reported_results","revenue_text":"$181 million"},"claim":"HALOZYME THERAPEUTICS, INC. reported the fourth quarter ended December 31, 2022 results: revenue $181 million, EPS $0.42 per diluted share.","evidence_excerpt":"Fourth Quarter Revenue Increased 78% YOY to $181 million; GAAP Diluted Earnings per Share of $0.42 and Non-GAAP Diluted Earnings per Share of $0.48","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001159036-23-000011","anchor_url":"https://secwatch.observer/filing/0001159036-23-000011#claim-e10f0527f9e778fe3c9ce8837b5f55b6f055aabf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000011/0001159036-23-000011-index.htm"},{"fact_type":"executive_change","fact_key":"991d3b921d","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2023-02-06T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-02-03","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Barbara Duncan was elected as Director at HALOZYME THERAPEUTICS, INC..","evidence_excerpt":"On February 3, 2023, Barbara Duncan was elected to the Board of Directors of Halozyme Therapeutics, Inc.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001159036-23-000006","anchor_url":"https://secwatch.observer/filing/0001159036-23-000006#claim-991d3b921d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000006/0001159036-23-000006-index.htm"},{"fact_type":"earnings_release","fact_key":"e2a70308d458326a9008ac621bb57e392d734e24","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2023-01-10T23:59:59+00:00","payload":{"eps_text":"$2.50 to $2.65","guidance_signal":"initiated","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"2023","report_date":"2023-01-10","result_type":"guidance_update","revenue_text":"$815 million to $845 million"},"claim":"HALOZYME THERAPEUTICS, INC. reported 2023 results: revenue $815 million to $845 million, EPS $2.50 to $2.65. Guidance initiated.","evidence_excerpt":"Halozyme expects total revenue of $815 million to $845 million","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001159036-23-000004","anchor_url":"https://secwatch.observer/filing/0001159036-23-000004#claim-e2a70308d458326a9008ac621bb57e392d734e24","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000004/0001159036-23-000004-index.htm"},{"fact_type":"earnings_release","fact_key":"e4c30abf88591d07243c7b7ac805161fdf28a421","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2022-11-08T23:59:59+00:00","payload":{"eps_text":"$0.44","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"third quarter ended September 30, 2022","report_date":"2022-11-08","result_type":"reported_results","revenue_text":"$209 million"},"claim":"HALOZYME THERAPEUTICS, INC. reported third quarter ended September 30, 2022 results: revenue $209 million, EPS $0.44. Guidance reaffirmed.","evidence_excerpt":"Revenue for the third quarter was $209 million compared to $115.8 million for the third quarter of 2021.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001159036-22-000058","anchor_url":"https://secwatch.observer/filing/0001159036-22-000058#claim-e4c30abf88591d07243c7b7ac805161fdf28a421","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903622000058/0001159036-22-000058-index.htm"},{"fact_type":"executive_change","fact_key":"66b8365bb7","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2022-03-15T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-03-11","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Moni Miyashita was elected as Director at HALOZYME THERAPEUTICS, INC..","evidence_excerpt":"On March 11, 2022, Moni Miyashita was elected to the Board of Directors of Halozyme Therapeutics, Inc.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001159036-22-000019","anchor_url":"https://secwatch.observer/filing/0001159036-22-000019#claim-66b8365bb7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903622000019/0001159036-22-000019-index.htm"},{"fact_type":"executive_change","fact_key":"beff4ad359","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2022-02-03T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-02-02","interim":false,"role":"Senior Vice President, Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Nicole LaBrosse was appointed as Senior Vice President, Chief Financial Officer at HALOZYME THERAPEUTICS, INC..","evidence_excerpt":"On February 2, 2022, Nicole LaBrosse was appointed as Senior Vice President, Chief Financial Officer of the Company, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001159036-22-000005","anchor_url":"https://secwatch.observer/filing/0001159036-22-000005#claim-beff4ad359","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903622000005/0001159036-22-000005-index.htm"},{"fact_type":"executive_change","fact_key":"86eecd123c","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2022-02-03T23:59:59+00:00","payload":{"action":"stepped down","action_category":"departure","departure_tone":"routine","effective_date":"2022-02-02","interim":false,"role":"Senior Vice President, Chief Financial Officer","role_category":"cfo","successor_name":"Nicole LaBrosse","successor_named":true},"claim":"Elaine Sun departed as Senior Vice President, Chief Financial Officer at HALOZYME THERAPEUTICS, INC..","evidence_excerpt":"On February 2, 2022, Halozyme Therapeutics, Inc. (the “Company”) announced that Elaine Sun is stepping down from her position as Senior Vice President, Chief Financial Officer of the Company, effective immediately, to pursue another opportunity.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001159036-22-000005","anchor_url":"https://secwatch.observer/filing/0001159036-22-000005#claim-86eecd123c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903622000005/0001159036-22-000005-index.htm"},{"fact_type":"executive_change","fact_key":"33d5ae05a2","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2021-12-13T23:59:59+00:00","payload":{"action":"will be appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-01-03","interim":false,"role":"Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary","role_category":"general_counsel","successor_name":null,"successor_named":false},"claim":"Mark Snyder was appointed as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary at HALOZYME THERAPEUTICS, INC..","evidence_excerpt":"Effective January 3, 2022, Mark Snyder will be appointed as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001159036-21-000059","anchor_url":"https://secwatch.observer/filing/0001159036-21-000059#claim-33d5ae05a2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903621000059/0001159036-21-000059-index.htm"},{"fact_type":"executive_change","fact_key":"f1b9ffb784","cik":1159036,"ticker":"HALO","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2021-12-13T23:59:59+00:00","payload":{"action":"will step down","action_category":"departure","departure_tone":"routine","effective_date":"2021-12-31","interim":false,"role":"Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary","role_category":"general_counsel","successor_name":"Mark Snyder","successor_named":true},"claim":"Masaru Matsuda departed as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary at HALOZYME THERAPEUTICS, INC..","evidence_excerpt":"Masaru Matsuda will step down from his position as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary of the Company, effective December 31, 2021, to pursue another opportunity.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001159036-21-000059","anchor_url":"https://secwatch.observer/filing/0001159036-21-000059#claim-f1b9ffb784","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903621000059/0001159036-21-000059-index.htm"}]}